Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Conditions
Brief summary
This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur. Giltertinib is a drug that is already FDA approved for the treatment of a specific type of leukemia. However, studies using ALK positive lung cancer cells demonstrate activity of gilteritinib against these resistant cells. Therefore, in this clinical trial, the investigators plan to study the effect of giltertinib in patients with ALK NSCLC.
Interventions
PROCEDUREEchocardiography
Undergo echocardiography
DRUGGilteritinib
Given PO
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
OTHERQuestionnaire Administration
Ancillary studies
PROCEDUREComputed Tomography
Undergo CT scan
PROCEDUREBiopsy
Undergo tissue biopsy
PROCEDUREBiospecimen Collection
Undergo blood sample collection
Sponsors
University of Michigan Rogel Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Stage IV (American Joint Committee on Cancer \[AJCC\] 8th edition) non-small cell lung cancer with an oncogenic ALK fusion * Histologies include adenocarcinoma, squamous cell carcinoma, adenosquamous adenocarcinoma, and NSCLC NOS (not otherwise specified) * The presence of an oncogenic ALK fusion established from any Clinical Laboratory Improvement Act (CLIA) certified laboratory * The patient must belong to one of the following treatment cohorts. * Cohort 1: Prior 1st generation ALK tyrosine kinase inhibitor (TKI) (crizotinib) and/or prior 2nd generation TKI (ceritinib, brigatinib, alectinib) and/or lorlatinib * Cohort 2: Prior 1st generation ALK TKI (crizotinib) and/or prior 2nd generation TKI (ceritinib, brigatinib, alectinib) and/or lorlatinib, and platinum-doublet chemotherapy * Cohort 3: Prior 1st generation ALK TK (crizotinib) and/or prior 2nd generation TKI (ceritinib, brigatinib, alectinib) and/ or lorlatinib, platinum-doublet chemotherapy, and any other number of antineoplastic agents (including immunotherapy, standard or investigational) * Age ≥ 18 * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Absolute neutrophil count (ANC) ≥ 1500/mcL * Platelets ≥ 100,000/mcL * Hemoglobin ≥ 9 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) * Measured or calculated creatinine clearance (CrCl) ≥ 50mL/min (calculated per Cockcroft-Gault formula) * Serum total bilirubin ≤ 1.5 X upper limit of normal (ULN) (per institutional guidelines) OR direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 ULN * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases * Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases * Albumin ≥ 2.5g/dL * Female subject of childbearing potential should have a negative serum pregnancy test within 21 days of enrollment prior to receiving the first dose of study medication * Female subjects of childbearing potential must be willing to use a highly effective method of contraception for the course of the study, through 180 days after the last dose of study medication. Note: Abstinence is acceptable, if patient documents that this is their usual lifestyle or preferred contraception method * Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 4 months after the last dose of study therapy. Note: Abstinence is acceptable, if patient documents that this is their usual lifestyle or preferred contraception method * Ability to swallow pills orally and per investigator's assessment, do not have any significant issues limiting absorption of drug * Ability to understand and the willingness to sign a written informed consent * Measurable disease per RECIST v1.1 criteria assessed per screening imaging * If a cancerous lesion is easily and safely accessible, a pre-treatment biopsy of this lesion is strongly encouraged but NOT required prior to first dose of gilteritinib. Archival or fresh tissue biopsy may be used as long as it was obtained prior to cycle 1 day 1 (C1D1) * At least 7 days must have elapsed since last anti-neoplastic TKI, chemotherapy, immunotherapy, or investigational agent prior to the first dose of gilteritinib
Exclusion criteria
* Received palliative radiation within 7 days of enrollment * Received prior therapy with a FLT3 inhibitor * Has a concurrent active malignancy receiving interventional therapy unless it is the investigator's opinion that the concurrent active malignancy will NOT significantly impact the survival of the patient (i.e. early stage breast cancer or prostate cancer on hormonal therapy, basal cell carcinoma awaiting Moh's or other surgery and the respective interventional therapy does NOT interact or interfere with gilteritinib. * Has known active and symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. * Subjects with previously treated brain metastases may participate provided they are stable (clinically asymptomatic, and ≥ 2 weeks since completion of treatment) and are not using steroids for at least 7 days prior to enrollment. A repeat MRI brain is not necessary to document stability * Patients with carcinomatous meningitis are excluded regardless of clinical stability * If a patient is found to have new/enlarging brain metastases on the screening MRI, the patient may be monitored closely and radiation could be delayed if the patient has no symptoms, there is no vasogenic edema, and there is no evidence of midline shift. * If the patient is symptomatic, there is vasogenic edema, and/or there is midline shift, the patient will need to undergo treatment for these brain metastases and meet
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events | Up to 30 days after last dose of gilteritinib | Safety will be assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. |
| Dose-limiting toxicities (DLT) | Cycle 1 day 1 up to cycle 2 day 1 (each cycle is 21 days) | Toxicities will be assessed by CTCAE v 5.0. DLT's will be defined as \>= grade 4 hematologic toxicities, \>= grade 3 febrile neutropenia, \>= grade 3 non-hematologic toxicities, and posterior reversible encephalopathy syndrome of any grade. Toxicity will be quantified by reporting the proportion of patients who experience a DLT at the identified maximum tolerated dose and by reporting a 95% confidence interval for this proportion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anti-tumor response | Up to 2 years after last dose of gilteritinib | Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. Best responses including complete response, partial response, stable disease and progressive disease will be determined by independent radiology assessment. |
| Progression-free survival (PFS) | From start of treatment to time of progression, assessed up to 2 years after last dose of gilteritinib | Determined by RECIST v 1.1. |
| Overall survival (OS) | Cycle 1 day 1 of study start to date of death from any cause, assessed up to 2 years from last dose of gilteritinib | Median OS and associated 95% confidence intervals will be assessed and reported using the Kaplan-Meier method. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAngel Qin
University of Michigan Rogel Cancer Center
Outcome results
None listed